| # | Thr. | #G | #C | Species | Tissues | GO BP | GO CC | GO MF | KEGG | miRNA | CHR |
| 1 | 3/2.8 | 56 | 3 | hsa | kd | cation transport (1.3e-05/ 2.1608/ 13/ 478) | integral to membrane (1.4e-06/1.7e+01/ 37/3638) | cation transmembrane transporter activity (1.7e-04/ 1.9566/ 11/ 437) | |||
| 2 | 3/2.4 | 64 | 4 | ggo, ppy, mml | ht | cardiac ventricle morphogenesis (3.5e-07/ 0.1253/ 6/ 25) | myofibril (1.1e-08/4.0e-01/ 9/ 86) | structural constituent of muscle (6.6e-04/ 0.1484/ 4/ 29) | Systemic lupus erythematosus (1.2e-09/ 0.461/10/ 52) | 6 (6.4e-03/ 3.932/14/ 721) | |
| 3 | 3/2.2 | 101 | 7 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (2.0e-17/ 1.2014/ 21/ 163) | myofibril (7.8e-20/6.0e-01/ 18/ 86) | structural constituent of muscle (7.2e-06/ 0.2279/ 6/ 29) | Dilated cardiomyopathy (9.2e-10/ 0.619/11/ 72) | ||
| 4 | 3/2.2 | 48 | 4 | hsa | br | membrane (1.1e-02/1.8e+01/ 29/5148) | transmembrane receptor activity (2.6e-02/ 2.1875/ 8/ 684) | ||||
| 5 | 3/2.2 | 104 | 6 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (1.8e-13/ 1.2494/ 18/ 163) | myofibril (7.1e-18/6.3e-01/ 17/ 86) | cytoskeletal protein binding (1.8e-04/ 3.1797/ 14/ 391) | Dilated cardiomyopathy (6.8e-07/ 0.657/ 9/ 72) | ||
| 6 | 3/2.2 | 144 | 7 | hsa, ptr, ppa, ppy, mml | kd | anterior/posterior pattern formation (1.4e-10/ 1.3565/ 16/ 116) | apical part of cell (9.4e-17/2.1e+00/ 24/ 170) | transmembrane transporter activity (2.5e-11/ 8.1323/ 35/ 712) | Collecting duct acid secretion (3.6e-05/ 0.181/ 5/ 21) | ||
| 7 | 3/2.2 | 36 | 9 | hsa, ptr, ppa, ggo, ppy, mml | cb | central nervous system development (2.3e-05/ 0.9605/ 9/ 362) | sequence-specific DNA binding transcription factor activity (1.1e-02/ 1.8761/ 8/ 708) | ||||
| 8 | 3/2.2 | 38 | 7 | hsa, ptr, ppa, ggo | cb | nervous system development (1.0e-04/ 2.8240/ 13/ 927) | synapse (3.2e-03/8.6e-01/ 6/ 290) | sequence-specific DNA binding (9.1e-03/ 1.3450/ 7/ 460) | |||
| 9 | 3/2.2 | 123 | 3 | ptr, mml | kd | multicellular organismal process (1.8e-03/33.0778/ 53/3300) | apical plasma membrane (3.1e-05/1.4e+00/ 10/ 135) | active transmembrane transporter activity (9.3e-08/ 2.6070/ 17/ 277) | |||
| 10 | 3/2.2 | 32 | 6 | hsa, ptr, ppa, ggo | cb | midbrain development (4.2e-04/ 0.0369/ 3/ 15) | collagen type XIII (2.8e-02/2.4e-03/ 1/ 1) | sequence-specific DNA binding (3.9e-04/ 1.0928/ 8/ 460) | |||
| 11 | 3/2 | 90 | 10 | hsa, ptr, ppa, ggo, ppy, mml | ht | cardiac muscle tissue development (1.1e-18/ 0.3865/ 16/ 57) | myofibril (4.0e-24/5.4e-01/ 20/ 86) | cytoskeletal protein binding (1.8e-06/ 2.8582/ 16/ 391) | Dilated cardiomyopathy (2.0e-10/ 0.544/11/ 72) | ||
| 12 | 3/2 | 135 | 11 | hsa, ptr, ppa, ggo, ppy, mml | kd | ion transport (1.3e-15/ 7.3623/ 39/ 663) | apical part of cell (1.5e-18/2.0e+00/ 25/ 170) | transmembrane transporter activity (1.7e-16/ 7.6769/ 41/ 712) | Aldosterone-regulated sodium reabsorption (2.1e-05/ 0.301/ 6/ 33) | ||
| 13 | 3/2 | 112 | 3 | hsa, mml | kd | vitamin D receptor signaling pathway (2.2e-04/ 0.0362/ 3/ 4) | apical part of cell (8.1e-05/1.5e+00/ 10/ 170) | active transmembrane transporter activity (7.0e-06/ 2.3539/ 14/ 277) | |||
| 14 | 3/1.8 | 91 | 12 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (6.2e-21/ 1.0892/ 23/ 163) | myofibril (1.5e-27/5.4e-01/ 22/ 86) | cytoskeletal protein binding (4.1e-08/ 2.8582/ 18/ 391) | Dilated cardiomyopathy (3.2e-12/ 0.507/12/ 72) | ||
| 15 | 3/1.8 | 133 | 10 | ggo | br, cb, ht, kd, lv | protein modification by small protein conjugation or removal (4.8e-02/ 2.8412/ 9/ 278) | Cul3-RING ubiquitin ligase complex (4.5e-02/1.0e-01/ 2/ 10) | small conjugating protein ligase activity (3.5e-02/ 1.7277/ 7/ 163) | |||
| 16 | 3/1.2 | 106 | 9 | ppy | br, cb, ht, kd, lv | antigen processing and presentation (1.7e-10/ 0.3163/ 10/ 37) | MHC class II protein complex (7.6e-10/6.9e-02/ 6/ 8) | TAP binding (3.9e-05/ 0.0247/ 3/ 3) | Antigen processing and presentation (3.2e-09/ 0.356/ 9/ 44) | 6 (2.1e-12/ 5.871/32/ 721) | |
| 17 | 3/1 | 99 | 13 | mml | br, cb, ht, kd, lv, ts | phototransduction, visible light (3.5e-02/ 0.0574/ 2/ 8) | Arachidonic acid metabolism (3.3e-02/ 0.250/ 3/ 40) | ||||
| 18 | 3/1 | 68 | 22 | hsa, ptr, ppy | br, cb, ht, kd, lv, ts, ht | eukaryotic translation elongation factor 1 complex (5.0e-02/5.0e-03/ 1/ 1) | |||||
| 19 | 2.8/2.8 | 108 | 3 | hsa, ggo | ts | defense response to bacterium (5.6e-06/ 0.5233/ 8/ 75) | extracellular region (1.7e-06/1.1e+01/ 31/1407) | sequence-specific DNA binding (8.2e-06/ 3.2365/ 16/ 460) | Olfactory transduction (1.2e-02/ 0.396/ 4/ 80) | X (2.1e-05/ 3.845/18/ 481) | |
| 20 | 2.8/2.6 | 72 | 4 | ptr, ppa, ppy | ht | oxidative phosphorylation (1.1e-04/ 0.3567/ 6/ 66) | mitochondrial membrane part (2.4e-06/3.6e-01/ 7/ 72) | oxidoreductase activity, acting on NADH or NADPH (5.3e-05/ 0.3233/ 6/ 58) | Parkinson's disease (2.1e-04/ 0.469/ 6/ 72) | ||
| 21 | 2.8/2.6 | 84 | 3 | hsa | kd | metal ion transport (4.7e-05/ 2.7801/ 14/ 410) | intrinsic to membrane (6.5e-08/2.6e+01/ 52/3717) | cation transmembrane transporter activity (2.6e-04/ 2.8750/ 13/ 437) | |||
| 22 | 2.8/2.6 | 87 | 3 | ptr, ppa, ppy | ht | electron transport chain (7.1e-04/ 0.5079/ 6/ 76) | mitochondrial part (7.7e-06/2.6e+00/ 14/ 430) | oxidoreductase activity, acting on NADH or NADPH (1.3e-04/ 0.3816/ 6/ 58) | Parkinson's disease (2.1e-03/ 0.450/ 5/ 72) | ||
| 23 | 2.8/2.4 | 69 | 4 | hsa | br | positive regulation of T cell proliferation (1.8e-02/ 0.1617/ 3/ 35) | membrane (5.7e-04/2.7e+01/ 43/5148) | signal transducer activity (1.1e-03/ 6.3860/ 18/1344) | |||
| 24 | 2.8/2.4 | 132 | 3 | ggo, ppy | kd | ion transport (1.5e-08/ 6.7759/ 28/ 663) | intrinsic to membrane (1.8e-07/4.0e+01/ 72/3717) | active transmembrane transporter activity (1.3e-13/ 2.7082/ 24/ 277) | Collecting duct acid secretion (1.7e-02/ 0.192/ 3/ 21) | ||
| 25 | 2.8/2.4 | 61 | 5 | hsa, ptr, ppa, ggo | cb | nervous system development (8.9e-07/ 4.1904/ 19/ 927) | synapse (1.9e-02/1.3e+00/ 6/ 290) | sequence-specific DNA binding (2.1e-04/ 2.0175/ 11/ 460) | Melanoma (1.7e-02/ 0.194/ 3/ 62) | ||
| 26 | 2.8/2.2 | 181 | 3 | ptr, mml | kd | ion transport (7.0e-08/ 9.7078/ 33/ 663) | apical part of cell (5.3e-10/2.5e+00/ 19/ 170) | active transmembrane transporter activity (8.4e-13/ 3.8978/ 27/ 277) | Collecting duct acid secretion (3.3e-03/ 0.263/ 4/ 21) | ||
| 27 | 2.8/2.2 | 141 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (1.2e-18/ 1.7460/ 25/ 163) | sarcomere (1.2e-27/7.4e-01/ 24/ 74) | structural constituent of muscle (8.7e-08/ 0.3233/ 8/ 29) | Cardiac muscle contraction (4.2e-13/ 0.677/14/ 53) | ||
| 28 | 2.8/2.2 | 178 | 3 | ppy, mml | kd | anterior/posterior pattern formation (1.7e-06/ 1.6871/ 13/ 116) | apical plasma membrane (7.0e-10/2.0e+00/ 17/ 135) | active transmembrane transporter activity (2.7e-12/ 3.7713/ 26/ 277) | Collecting duct acid secretion (3.0e-02/ 0.241/ 3/ 21) | ||
| 29 | 2.8/2.2 | 175 | 4 | ggo, mml | kd | ion transport (2.9e-10/ 9.7078/ 37/ 663) | apical part of cell (3.9e-10/2.5e+00/ 19/ 170) | active transmembrane transporter activity (2.8e-16/ 3.8978/ 31/ 277) | Collecting duct acid secretion (2.0e-04/ 0.263/ 5/ 21) | ||
| 30 | 2.8/2.2 | 40 | 9 | hsa, ptr, ppa, ppy, mml | lv | organic acid catabolic process (6.6e-06/ 0.3585/ 7/ 96) | insoluble fraction (2.1e-05/2.1e+00/ 12/ 626) | carboxylic acid transmembrane transporter activity (1.8e-04/ 0.2303/ 5/ 70) | Complement and coagulation cascades (2.4e-04/ 0.274/ 5/ 50) | ||
| 31 | 2.8/2.2 | 110 | 3 | ppa, ggo | ht | muscle contraction (7.7e-08/ 1.2814/ 13/ 163) | sarcomere (3.6e-07/6.0e-01/ 9/ 74) | structural constituent of muscle (2.0e-04/ 0.2385/ 5/ 29) | Cardiac muscle contraction (1.1e-03/ 0.387/ 5/ 53) | ||
| 32 | 2.8/2.2 | 63 | 7 | hsa, ptr, ppa, ggo | cb | nervous system development (1.0e-06/ 4.6459/ 20/ 927) | synapse (2.5e-02/1.3e+00/ 6/ 290) | sequence-specific DNA binding (8.6e-03/ 2.1857/ 9/ 460) | |||
| 33 | 2.8/2.2 | 165 | 4 | ppa, ppy | kd | anterior/posterior pattern formation (3.9e-11/ 1.4705/ 17/ 116) | apical part of cell (1.1e-12/2.3e+00/ 21/ 170) | sequence-specific DNA binding (1.9e-09/ 5.6743/ 27/ 460) | Collecting duct acid secretion (1.3e-04/ 0.241/ 5/ 21) | ||
| 34 | 2.8/2 | 60 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (2.2e-07/ 4.2815/ 20/ 927) | synapse (9.3e-04/1.3e+00/ 8/ 290) | glutamate receptor activity (4.9e-03/ 0.1030/ 3/ 23) | Neuroactive ligand-receptor interaction (4.7e-02/ 0.644/ 4/206) | ||
| 35 | 2.8/2 | 117 | 3 | ptr | ht, kd, lv | immune response (1.1e-09/ 5.1199/ 26/ 521) | Cajal body (2.6e-02/2.6e-01/ 3/ 28) | chemokine activity (3.4e-04/ 0.2686/ 5/ 28) | Toll-like receptor signaling pathway (4.2e-04/ 0.792/ 7/ 76) | ||
| 36 | 2.8/2 | 189 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | ion transport (1.7e-12/ 9.9685/ 41/ 663) | apical part of cell (2.6e-16/2.7e+00/ 26/ 170) | transmembrane transporter activity (2.3e-14/10.5395/ 45/ 712) | Aldosterone-regulated sodium reabsorption (1.2e-04/ 0.413/ 6/ 33) | ||
| 37 | 2.8/2 | 47 | 8 | hsa, ptr, ppa, ppy, mml | lv | carboxylic acid metabolic process (1.0e-07/ 2.0368/ 15/ 482) | insoluble fraction (5.1e-04/2.5e+00/ 11/ 626) | carboxylic acid transmembrane transporter activity (4.8e-04/ 0.2878/ 5/ 70) | Retinol metabolism (4.7e-04/ 0.150/ 4/ 25) | ||
| 38 | 2.8/2 | 42 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | organic acid catabolic process (5.9e-07/ 0.3868/ 8/ 96) | extracellular region (4.7e-08/4.9e+00/ 21/1407) | endopeptidase inhibitor activity (1.2e-03/ 0.3576/ 5/ 103) | Complement and coagulation cascades (1.7e-07/ 0.248/ 7/ 50) | ||
| 39 | 2.8/2 | 120 | 4 | mml | ht, kd | regulation of gluconeogenesis (4.2e-02/ 0.0653/ 2/ 7) | extracellular region (6.8e-05/1.3e+01/ 31/1407) | hormone activity (1.3e-03/ 0.5987/ 6/ 72) | |||
| 40 | 2.8/1.8 | 126 | 12 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (3.4e-21/ 1.5377/ 26/ 163) | sarcomere (3.3e-30/6.6e-01/ 25/ 74) | cytoskeletal protein binding (1.0e-09/ 3.9300/ 23/ 391) | Dilated cardiomyopathy (8.4e-13/ 0.732/14/ 72) | ||
| 41 | 2.8/1.8 | 52 | 6 | hsa | br | photoreceptor cell maintenance (1.8e-03/ 0.0637/ 3/ 18) | membrane (1.3e-03/2.1e+01/ 34/5148) | signal transducer activity (1.9e-03/ 4.4211/ 14/1344) | |||
| 42 | 2.8/1.8 | 81 | 3 | ppy, mml | lv | immune response (2.9e-04/ 3.3279/ 14/ 521) | extracellular region (2.4e-04/8.9e+00/ 23/1407) | peptide binding (4.4e-02/ 0.9306/ 5/ 152) | Hematopoietic cell lineage (3.5e-02/ 0.550/ 4/ 68) | ||
| 43 | 2.8/1.8 | 31 | 12 | hsa, ptr, ppa, ggo, ppy, mml | lv | humoral immune response mediated by circulating immunoglobulin (2.2e-08/ 0.0767/ 6/ 26) | extracellular region (8.4e-08/3.8e+00/ 18/1407) | serine-type endopeptidase inhibitor activity (1.2e-03/ 0.1752/ 4/ 71) | Complement and coagulation cascades (8.2e-10/ 0.209/ 8/ 50) | ||
| 44 | 2.8/1.8 | 68 | 4 | ppy, mml | lv | amide biosynthetic process (1.9e-02/ 0.0371/ 2/ 7) | extracellular region (8.9e-06/7.4e+00/ 23/1407) | ||||
| 45 | 2.8/1.4 | 37 | 8 | hsa, ptr, ggo | br | oligodendrocyte differentiation (2.7e-03/ 0.0743/ 3/ 27) | membrane part (8.7e-04/1.2e+01/ 24/4287) | ||||
| 46 | 2.8/1.2 | 120 | 16 | hsa | br, cb, ht, kd, lv, ts | ventricular system development (2.4e-02/ 0.0457/ 2/ 5) | Cul4A-RING ubiquitin ligase complex (1.5e-02/5.3e-02/ 2/ 6) | translation factor activity, nucleic acid binding (2.9e-02/ 0.4786/ 4/ 54) | |||
| 47 | 2.8/1.2 | 71 | 4 | mml | kd, lv | response to external stimulus (5.1e-03/ 2.8970/ 11/ 536) | extracellular region (1.6e-02/7.8e+00/ 17/1407) | C-X-C chemokine receptor activity (1.2e-02/ 0.0329/ 2/ 6) | |||
| 48 | 2.6/2.8 | 128 | 3 | ptr, ppy | ht | muscle contraction (5.1e-05/ 1.6018/ 11/ 163) | mitochondrial part (1.2e-05/3.9e+00/ 17/ 430) | oxidoreductase activity, acting on NADH or NADPH (1.1e-03/ 0.5830/ 6/ 58) | Parkinson's disease (5.4e-04/ 0.826/ 7/ 72) | ||
| 49 | 2.6/2.8 | 150 | 3 | hsa | kd | ion transport (9.2e-08/ 7.8184/ 29/ 663) | integral to membrane (2.5e-10/4.4e+01/ 83/3638) | transmembrane transporter activity (2.6e-08/ 8.0022/ 30/ 712) | Glycosphingolipid biosynthesis - lacto and neolacto series (2.5e-02/ 0.223/ 3/ 19) | ||
| 50 | 2.6/2.6 | 115 | 3 | ptr, ppa | cb | nervous system development (1.2e-03/ 7.8343/ 21/ 927) | synapse (3.7e-02/2.5e+00/ 8/ 290) | nucleic acid binding (4.7e-02/16.5859/ 28/1973) | |||
| 51 | 2.6/2.6 | 175 | 3 | hsa | ht | muscle system process (2.6e-10/ 2.5221/ 20/ 177) | sarcomere (4.5e-12/1.0e+00/ 15/ 74) | structural constituent of muscle (6.1e-07/ 0.4213/ 8/ 29) | Dilated cardiomyopathy (7.8e-06/ 1.145/10/ 72) | ||
| 52 | 2.6/2.6 | 106 | 3 | ppa, ppy | lv | defense response (7.0e-07/ 4.6680/ 21/ 522) | extracellular region (1.3e-05/1.3e+01/ 32/1407) | signal transducer activity (1.8e-04/11.9123/ 29/1344) | Chemokine signaling pathway (1.0e-02/ 1.434/ 7/141) | ||
| 53 | 2.6/2.4 | 91 | 5 | hsa, ptr, mml | lv | small molecule metabolic process (1.4e-07/10.1933/ 32/1313) | high-density lipoprotein particle (6.1e-05/9.9e-02/ 4/ 13) | carboxylic acid transmembrane transporter activity (6.9e-04/ 0.5309/ 6/ 70) | Metabolic pathways (2.1e-03/ 7.974/19/805) | ||
| 54 | 2.6/2.4 | 171 | 4 | mml | ht, kd | rhombomere development (4.0e-02/ 0.0658/ 2/ 5) | extracellular region (5.6e-05/1.8e+01/ 39/1407) | monoamine transmembrane transporter activity (8.3e-04/ 0.0608/ 3/ 5) | |||
| 55 | 2.6/2.4 | 229 | 4 | hsa, ptr, ppa, ggo | ht | muscle contraction (6.0e-20/ 2.8352/ 31/ 163) | sarcomere (8.3e-27/1.2e+00/ 27/ 74) | structural constituent of muscle (6.7e-09/ 0.5167/ 10/ 29) | Parkinson's disease (5.4e-12/ 1.483/17/ 72) | ||
| 56 | 2.6/2.4 | 209 | 3 | ptr, ppa | kd | embryonic skeletal system development (1.8e-07/ 1.1256/ 12/ 69) | apical part of cell (4.3e-09/2.9e+00/ 19/ 170) | anion transmembrane transporter activity (5.5e-08/ 1.8438/ 15/ 118) | Collecting duct acid secretion (2.0e-04/ 0.263/ 5/ 21) | ||
| 57 | 2.6/2.4 | 129 | 3 | hsa | br | cytoskeleton organization (3.5e-02/ 3.7944/ 11/ 394) | scavenger receptor activity (9.3e-03/ 0.3293/ 4/ 34) | ||||
| 58 | 2.6/2.4 | 81 | 4 | hsa, ptr, mml | lv | alcohol metabolic process (5.4e-08/ 2.5059/ 17/ 375) | insoluble fraction (3.5e-04/4.2e+00/ 15/ 626) | carbohydrate kinase activity (6.7e-03/ 0.1181/ 3/ 17) | Metabolic pathways (6.4e-03/ 7.345/17/805) | ||
| 59 | 2.6/2.2 | 255 | 4 | ptr, ggo, mml | kd | ion transport (3.2e-13/13.6822/ 50/ 663) | apical plasma membrane (6.1e-16/2.8e+00/ 26/ 135) | active transmembrane transporter activity (5.1e-18/ 5.5937/ 39/ 277) | Aldosterone-regulated sodium reabsorption (1.0e-03/ 0.628/ 6/ 33) | ||
| 60 | 2.6/2.2 | 115 | 8 | hsa, ptr, ppa, ppy, mml | lv | organic acid metabolic process (3.6e-12/ 5.0147/ 29/ 486) | extracellular region (9.3e-11/1.4e+01/ 43/1407) | endopeptidase inhibitor activity (3.9e-08/ 0.9976/ 12/ 103) | Complement and coagulation cascades (3.1e-11/ 0.769/13/ 50) | ||
| 61 | 2.6/2.2 | 239 | 6 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (3.3e-21/ 3.0274/ 33/ 163) | myofibril (8.6e-30/1.5e+00/ 31/ 86) | structural constituent of muscle (4.7e-10/ 0.5406/ 11/ 29) | Cardiac muscle contraction (6.4e-13/ 1.064/16/ 53) | ||
| 62 | 2.6/2.2 | 230 | 5 | hsa, mml | kd | ion transport (3.7e-17/12.2488/ 53/ 663) | apical part of cell (1.3e-20/3.2e+00/ 32/ 170) | transmembrane transporter activity (6.5e-19/12.6864/ 58/ 712) | Aldosterone-regulated sodium reabsorption (1.9e-05/ 0.482/ 7/ 33) | ||
| 63 | 2.6/2.2 | 216 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (4.3e-20/ 2.8032/ 31/ 163) | myofibril (4.6e-27/1.3e+00/ 28/ 86) | structural constituent of muscle (5.7e-09/ 0.5061/ 10/ 29) | Hypertrophic cardiomyopathy (HCM) (1.4e-12/ 1.349/17/ 69) | ||
| 64 | 2.6/2.2 | 260 | 6 | hsa, ptr, ggo, ppy, mml | kd | ion transport (2.3e-14/13.7473/ 52/ 663) | apical part of cell (2.7e-19/3.6e+00/ 32/ 170) | active transmembrane transporter activity (5.8e-18/ 5.6949/ 39/ 277) | Aldosterone-regulated sodium reabsorption (9.5e-04/ 0.619/ 6/ 33) | ||
| 65 | 2.6/2.2 | 263 | 4 | ptr, ppy, mml | kd | ion transport (2.7e-12/13.9428/ 49/ 663) | apical part of cell (4.7e-17/3.6e+00/ 30/ 170) | active transmembrane transporter activity (3.0e-17/ 5.6949/ 38/ 277) | Collecting duct acid secretion (1.1e-03/ 0.394/ 5/ 21) | ||
| 66 | 2.6/2.2 | 70 | 4 | hsa, ppy | lv | bile acid catabolic process (4.2e-03/ 0.0165/ 2/ 3) | extracellular region (2.0e-08/7.9e+00/ 28/1407) | endopeptidase inhibitor activity (1.1e-04/ 0.5835/ 7/ 103) | Retinol metabolism (1.1e-03/ 0.189/ 4/ 25) | ||
| 67 | 2.6/2.2 | 207 | 5 | hsa, ptr, ppa | kd | ion transport (9.9e-14/10.9458/ 45/ 663) | apical part of cell (1.0e-16/2.9e+00/ 27/ 170) | transmembrane transporter activity (2.0e-14/11.3852/ 47/ 712) | Aldosterone-regulated sodium reabsorption (1.0e-04/ 0.404/ 6/ 33) | ||
| 68 | 2.6/2.2 | 238 | 4 | ppy, mml | kd | ion transport (3.2e-10/12.7049/ 43/ 663) | apical part of cell (3.1e-14/3.3e+00/ 26/ 170) | active transmembrane transporter activity (4.8e-14/ 5.0874/ 32/ 277) | Collecting duct acid secretion (5.4e-04/ 0.328/ 5/ 21) | ||
| 69 | 2.6/2.2 | 214 | 4 | ptr, ppa, ppy | kd | anterior/posterior pattern formation (3.3e-10/ 1.9721/ 18/ 116) | apical part of cell (2.2e-17/3.0e+00/ 28/ 170) | transmembrane transporter activity (3.7e-11/11.5154/ 42/ 712) | Collecting duct acid secretion (1.3e-05/ 0.285/ 6/ 21) | ||
| 70 | 2.6/2.2 | 103 | 4 | ppy, mml | lv | defense response (1.4e-07/ 4.2577/ 21/ 522) | extracellular region (9.7e-09/1.2e+01/ 36/1407) | Gram-negative bacterial cell surface binding (6.1e-03/ 0.0236/ 2/ 3) | Steroid hormone biosynthesis (2.4e-02/ 0.218/ 3/ 22) | ||
| 71 | 2.6/2.2 | 112 | 7 | hsa, ptr, ppa, ggo | cb | nervous system development (1.7e-05/ 7.4699/ 24/ 927) | synapse (8.9e-03/2.4e+00/ 9/ 290) | sequence-specific DNA binding transcription factor activity (2.2e-03/ 5.8224/ 17/ 708) | |||
| 72 | 2.6/2 | 255 | 10 | hsa, ptr, ppa, ggo, ppy, mml | kd | ion transport (3.6e-16/13.3564/ 54/ 663) | apical part of cell (1.5e-19/3.5e+00/ 32/ 170) | transmembrane transporter activity (7.7e-18/14.2478/ 59/ 712) | Aldosterone-regulated sodium reabsorption (4.6e-04/ 0.533/ 6/ 33) | ||
| 73 | 2.6/2 | 119 | 4 | hsa | br | oligodendrocyte differentiation (3.9e-03/ 0.2361/ 4/ 27) | membrane (5.5e-03/4.7e+01/ 65/5148) | scavenger receptor activity (6.2e-03/ 0.2889/ 4/ 34) | Axon guidance (4.7e-02/ 0.995/ 5/106) | ||
| 74 | 2.6/2 | 104 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | acute inflammatory response (2.4e-09/ 0.7435/ 12/ 78) | extracellular region (2.3e-17/1.3e+01/ 50/1407) | endopeptidase inhibitor activity (1.0e-10/ 0.9223/ 14/ 103) | Complement and coagulation cascades (4.4e-14/ 0.717/15/ 50) | ||
| 75 | 2.6/2 | 95 | 10 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (6.5e-08/ 6.5590/ 26/ 927) | synapse (3.4e-03/2.1e+00/ 9/ 290) | sequence-specific DNA binding transcription factor activity (1.1e-02/ 4.9814/ 14/ 708) | |||
| 76 | 2.6/2 | 197 | 3 | ptr, ppa | kd, lv, br | immune response (3.0e-18/ 8.4990/ 46/ 521) | external side of plasma membrane (1.4e-05/1.9e+00/ 12/ 121) | chemokine activity (1.6e-05/ 0.4452/ 7/ 28) | Leishmaniasis (4.8e-05/ 1.090/ 9/ 51) | ||
| 77 | 2.6/1.8 | 199 | 11 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (2.7e-22/ 2.5148/ 32/ 163) | myofibril (2.5e-29/1.2e+00/ 29/ 86) | structural constituent of muscle (2.8e-09/ 0.4664/ 10/ 29) | Cardiac muscle contraction (1.1e-14/ 0.981/17/ 53) | ||
| 78 | 2.6/1.8 | 257 | 13 | hsa, ptr, ppa, ggo, ppy, mml | kd | ion transport (1.5e-13/13.4216/ 50/ 663) | apical part of cell (2.3e-18/3.5e+00/ 31/ 170) | secondary active transmembrane transporter activity (1.1e-14/ 3.2018/ 27/ 160) | Aldosterone-regulated sodium reabsorption (3.9e-04/ 0.516/ 6/ 33) | ||
| 79 | 2.6/1.8 | 85 | 6 | hsa | br | visual perception (3.2e-03/ 1.0202/ 7/ 179) | intrinsic to membrane (6.3e-03/2.4e+01/ 38/3717) | receptor activity (4.9e-03/ 5.8012/ 16/ 992) | |||
| 80 | 2.6/1.8 | 112 | 4 | mml | kd, lv | detection of visible light (9.1e-03/ 0.1238/ 3/ 15) | photoreceptor outer segment membrane (3.5e-03/2.5e-02/ 2/ 3) | C-X-C chemokine receptor activity (2.4e-02/ 0.0504/ 2/ 6) | |||
| 81 | 2.6/1.6 | 202 | 13 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (3.2e-24/ 2.5789/ 34/ 163) | contractile fiber (3.1e-33/1.4e+00/ 33/ 94) | structural constituent of muscle (1.8e-13/ 0.4717/ 13/ 29) | Dilated cardiomyopathy (2.9e-13/ 1.201/17/ 72) | ||
| 82 | 2.6/1.6 | 207 | 9 | ppy | br, cb, ht, kd, lv | antigen processing and presentation (7.5e-08/ 0.6254/ 10/ 37) | MHC class II protein complex (2.8e-08/1.3e-01/ 6/ 8) | TAP binding (2.3e-04/ 0.0474/ 3/ 3) | Systemic lupus erythematosus (1.7e-15/ 0.881/17/ 52) | 6 (4.7e-14/11.958/49/ 721) | |
| 83 | 2.6/1.6 | 95 | 6 | hsa, ptr | br | oligodendrocyte differentiation (9.7e-05/ 0.1910/ 5/ 27) | membrane (2.4e-02/3.9e+01/ 53/5148) | RNA polymerase II transcription factor activity, enhancer binding (2.6e-02/ 0.2083/ 3/ 30) | |||
| 84 | 2.6/1.4 | 47 | 13 | hsa, ptr, ppa, ggo, ppy, mml | br | ion transport (6.1e-06/ 2.4758/ 14/ 663) | ion channel complex (3.3e-09/6.8e-01/ 11/ 170) | voltage-gated cation channel activity (2.7e-08/ 0.4097/ 9/ 118) | Neuroactive ligand-receptor interaction (7.9e-05/ 0.698/ 7/206) | ||
| 85 | 2.6/1.4 | 124 | 12 | hsa | br, ht, kd, lv, ts | vacuole organization (1.6e-02/ 0.3679/ 4/ 39) | FHF complex (1.1e-02/4.6e-02/ 2/ 5) | adenylyltransferase activity (8.1e-03/ 0.1292/ 3/ 14) | |||
| 86 | 2.6/1.2 | 32 | 20 | hsa, ptr, ppa, ggo, ppy, mml | br | ion transport (5.0e-04/ 1.4985/ 9/ 663) | cation channel complex (7.4e-07/3.1e-01/ 7/ 113) | voltage-gated cation channel activity (4.8e-07/ 0.2588/ 7/ 118) | Neuroactive ligand-receptor interaction (3.6e-04/ 0.376/ 5/206) | ||
| 87 | 2.6/1.2 | 49 | 10 | hsa, ptr, ggo | br | oligodendrocyte differentiation (4.2e-06/ 0.0955/ 5/ 27) | intrinsic to membrane (7.7e-05/1.4e+01/ 29/3717) | RNA polymerase II transcription factor activity, enhancer binding (5.1e-03/ 0.1042/ 3/ 30) | |||
| 88 | 2.6/1 | 28 | 21 | hsa, ptr, ppa, ggo, ppy, mml | br | ion transport (1.2e-03/ 1.3031/ 8/ 663) | cation channel complex (2.8e-07/2.7e-01/ 7/ 113) | voltage-gated cation channel activity (1.8e-07/ 0.2264/ 7/ 118) | Neuroactive ligand-receptor interaction (2.7e-02/ 0.269/ 3/206) | ||
| 89 | 2.4/2.8 | 107 | 4 | hsa, ptr, ppa | ts | sex differentiation (2.8e-03/ 0.9906/ 7/ 144) | sequence-specific DNA binding transcription factor activity (1.8e-04/ 5.2401/ 18/ 708) | X (3.6e-04/ 3.773/16/ 481) | |||
| 90 | 2.4/2.8 | 247 | 3 | hsa | kd | ion transport (9.6e-10/13.1610/ 43/ 663) | apical plasma membrane (2.3e-14/2.7e+00/ 24/ 135) | transmembrane transporter activity (2.4e-13/13.5972/ 50/ 712) | Collecting duct acid secretion (7.1e-04/ 0.350/ 5/ 21) | ||
| 91 | 2.4/2.6 | 174 | 3 | ggo, ppy | lv | immune system process (7.0e-17/11.8311/ 51/ 819) | extracellular region (2.1e-17/2.0e+01/ 66/1407) | carbohydrate binding (2.8e-05/ 3.9164/ 17/ 273) | Cytokine-cytokine receptor interaction (5.9e-04/ 3.768/14/198) | ||
| 92 | 2.4/2.6 | 261 | 3 | ptr, ppa | ht | muscle contraction (7.9e-10/ 3.3638/ 22/ 163) | myofibril (3.3e-12/1.6e+00/ 18/ 86) | actin binding (8.7e-04/ 5.2039/ 17/ 252) | Hypertrophic cardiomyopathy (HCM) (9.2e-08/ 1.457/13/ 69) | ||
| 93 | 2.4/2.4 | 195 | 4 | ppy, mml | lv | innate immune response (4.2e-09/ 2.6431/ 19/ 164) | extracellular region (4.1e-15/2.3e+01/ 67/1407) | endopeptidase inhibitor activity (5.2e-06/ 1.5906/ 12/ 103) | Complement and coagulation cascades (2.1e-07/ 1.017/11/ 50) | ||
| 94 | 2.4/2.4 | 231 | 3 | hsa | br | oligodendrocyte differentiation (4.4e-03/ 0.4749/ 5/ 27) | membrane (6.3e-03/9.3e+01/117/5148) | receptor activity (2.5e-02/17.4035/ 31/ 992) | Axon guidance (2.5e-02/ 1.686/ 7/106) | ||
| 95 | 2.4/2.4 | 290 | 3 | hsa | ht | muscle contraction (5.3e-16/ 3.6842/ 30/ 163) | sarcomere (1.6e-26/1.6e+00/ 29/ 74) | structural constituent of muscle (1.0e-11/ 0.6731/ 13/ 29) | Dilated cardiomyopathy (1.1e-07/ 1.783/14/ 72) | ||
| 96 | 2.4/2.4 | 287 | 3 | ptr, ppa | kd | skeletal system development (3.4e-08/ 4.9745/ 24/ 223) | apical part of cell (8.4e-11/3.9e+00/ 24/ 170) | anion transmembrane transporter activity (7.2e-08/ 2.5446/ 17/ 118) | Aldosterone-regulated sodium reabsorption (8.3e-05/ 0.611/ 7/ 33) | ||
| 97 | 2.4/2.4 | 305 | 4 | ptr, ppa, ppy, mml | ht | muscle contraction (3.2e-15/ 3.9565/ 30/ 163) | sarcomere (1.6e-23/1.7e+00/ 27/ 74) | cytoskeletal protein binding (5.9e-09/ 9.6821/ 35/ 391) | Cardiac muscle contraction (1.7e-10/ 1.340/15/ 53) | ||
| 98 | 2.4/2.4 | 335 | 3 | hsa, ppy, mml | ht | muscle contraction (1.1e-19/ 4.2928/ 36/ 163) | myofibril (3.3e-30/2.2e+00/ 35/ 86) | structural constituent of muscle (1.0e-13/ 0.7738/ 15/ 29) | Cardiac muscle contraction (5.0e-14/ 1.520/19/ 53) | ||
| 99 | 2.4/2.4 | 190 | 5 | ppa, ggo, ppy | lv | immune system process (8.6e-17/13.6822/ 55/ 819) | extracellular region (1.4e-17/2.3e+01/ 71/1407) | peptidase regulator activity (6.8e-11/ 2.0828/ 19/ 131) | Complement and coagulation cascades (2.9e-12/ 0.991/15/ 50) | ||
| 100 | 2.4/2.4 | 162 | 4 | ppa, ppy | lv | defense response (2.6e-09/ 7.0277/ 30/ 522) | extracellular region (1.7e-13/1.9e+01/ 57/1407) | endopeptidase inhibitor activity (8.1e-06/ 1.3459/ 11/ 103) | Complement and coagulation cascades (3.3e-09/ 0.886/12/ 50) | ||
| 101 | 2.4/2.4 | 97 | 5 | hsa, ptr, ppa, ggo | ts | reproductive process (7.6e-04/ 3.6933/ 14/ 637) | sequence-specific DNA binding transcription factor activity (2.8e-02/ 4.3991/ 12/ 708) | X (1.4e-03/ 3.342/14/ 481) | |||
| 102 | 2.4/2.4 | 252 | 4 | ptr, ppa, ppy | ht | muscle contraction (4.1e-14/ 3.3958/ 27/ 163) | sarcomere (7.9e-16/1.4e+00/ 20/ 74) | structural constituent of muscle (8.1e-06/ 0.6042/ 8/ 29) | Hypertrophic cardiomyopathy (HCM) (2.3e-08/ 1.583/14/ 69) | ||
| 103 | 2.4/2.4 | 352 | 3 | hsa, mml | ht | muscle system process (1.3e-22/ 4.7833/ 41/ 177) | contractile fiber (1.8e-29/2.5e+00/ 36/ 94) | structural constituent of muscle (4.0e-15/ 0.7791/ 16/ 29) | Dilated cardiomyopathy (7.4e-08/ 2.046/15/ 72) | ||
| 104 | 2.4/2.2 | 198 | 8 | hsa, ptr, ppa, ppy, mml | lv | organic acid metabolic process (3.5e-10/ 8.6445/ 35/ 486) | extracellular region (2.6e-16/2.4e+01/ 71/1407) | endopeptidase inhibitor activity (2.7e-09/ 1.7317/ 16/ 103) | Complement and coagulation cascades (1.1e-15/ 1.225/19/ 50) | ||
| 105 | 2.4/2.2 | 320 | 8 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (1.9e-17/ 4.1166/ 33/ 163) | myofibril (3.2e-26/2.0e+00/ 31/ 86) | cytoskeletal protein binding (1.7e-10/ 9.8250/ 38/ 391) | Cardiac muscle contraction (7.6e-13/ 1.547/18/ 53) | ||
| 106 | 2.4/2.2 | 291 | 4 | hsa, ggo | ht | muscle contraction (7.4e-18/ 3.6681/ 32/ 163) | contractile fiber part (2.3e-28/1.9e+00/ 32/ 86) | structural constituent of muscle (9.8e-12/ 0.6704/ 13/ 29) | Cardiac muscle contraction (2.2e-11/ 1.395/16/ 53) | ||
| 107 | 2.4/2.2 | 189 | 4 | mml | kd, lv | response to external stimulus (6.7e-03/ 7.4796/ 19/ 536) | photoreceptor outer segment membrane (8.5e-03/4.2e-02/ 2/ 3) | vitamin transporter activity (3.4e-03/ 0.2485/ 4/ 17) | |||
| 108 | 2.4/2.2 | 180 | 7 | hsa, ptr, ppa, ggo | cb | multicellular organismal development (7.7e-05/33.0607/ 59/2386) | nucleus (2.2e-03/4.9e+01/ 71/3707) | sequence-specific DNA binding (7.1e-05/ 6.2628/ 21/ 460) | |||
| 109 | 2.4/2.2 | 291 | 3 | ppa, ggo | ht | muscle system process (1.4e-13/ 3.8962/ 28/ 177) | contractile fiber part (3.9e-20/1.9e+00/ 26/ 86) | structural constituent of muscle (1.4e-05/ 0.6545/ 8/ 29) | Dilated cardiomyopathy (8.4e-09/ 1.746/15/ 72) | MT (6.0e-04/ 0.238/ 5/ 11) | |
| 110 | 2.4/2.2 | 340 | 5 | hsa, ggo, mml | ht | muscle contraction (1.0e-21/ 4.2288/ 38/ 163) | contractile fiber (9.8e-30/2.4e+00/ 36/ 94) | structural constituent of muscle (1.0e-13/ 0.7764/ 15/ 29) | Cardiac muscle contraction (1.4e-11/ 1.354/16/ 53) | ||
| 111 | 2.4/2 | 119 | 5 | hsa | kd, lv | regulation of receptor activity (2.3e-02/ 0.1830/ 3/ 19) | intrinsic to membrane (5.2e-04/3.5e+01/ 56/3717) | cytokine receptor activity (2.7e-02/ 0.4656/ 4/ 49) | |||
| 112 | 2.4/2 | 181 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | response to wounding (8.6e-16/ 8.2042/ 42/ 494) | extracellular region (7.0e-23/2.2e+01/ 77/1407) | endopeptidase inhibitor activity (7.8e-09/ 1.5906/ 15/ 103) | Complement and coagulation cascades (3.7e-20/ 1.173/22/ 50) | ||
| 113 | 2.4/2 | 194 | 3 | ppy | kd, lv | immune system process (1.4e-12/12.9578/ 47/ 819) | extracellular region (2.9e-07/2.2e+01/ 51/1407) | growth factor activity (1.6e-03/ 2.0417/ 10/ 133) | Cytokine-cytokine receptor interaction (6.8e-03/ 3.200/11/198) | 6 (2.3e-02/10.450/24/ 721) | |
| 114 | 2.4/2 | 210 | 4 | hsa | br | oligodendrocyte differentiation (2.5e-03/ 0.4113/ 5/ 27) | membrane (1.3e-04/8.2e+01/112/5148) | scavenger receptor activity (3.4e-02/ 0.5157/ 4/ 34) | |||
| 115 | 2.4/1.8 | 164 | 11 | hsa, ptr, ppa, ggo, ppy, mml | cb | central nervous system development (2.9e-05/ 4.3400/ 18/ 362) | dendrite (2.5e-02/1.8e+00/ 7/ 149) | sequence-specific DNA binding (6.6e-04/ 5.6743/ 18/ 460) | Long-term depression (4.1e-03/ 0.521/ 5/ 54) | ||
| 116 | 2.4/1.8 | 325 | 11 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (8.1e-20/ 4.2448/ 36/ 163) | myofibril (1.8e-29/2.1e+00/ 34/ 86) | cytoskeletal protein binding (7.0e-12/10.1466/ 41/ 391) | Cardiac muscle contraction (2.1e-12/ 1.658/18/ 53) | ||
| 117 | 2.4/1.8 | 239 | 4 | ptr, ppa | kd, lv, br | immune system process (5.7e-21/16.2577/ 67/ 819) | external side of plasma membrane (1.9e-03/2.3e+00/ 10/ 121) | chemokine activity (6.5e-04/ 0.5424/ 6/ 28) | Phagosome (3.6e-06/ 2.352/14/ 93) | ||
| 118 | 2.4/1.8 | 295 | 9 | ppy | br, cb, ht, kd, lv | antigen processing and presentation (1.0e-07/ 0.8726/ 11/ 37) | MHC class II protein complex (1.9e-07/1.8e-01/ 6/ 8) | TAP binding (5.7e-04/ 0.0674/ 3/ 3) | Systemic lupus erythematosus (5.0e-13/ 1.261/17/ 52) | 6 (3.0e-09/16.645/50/ 721) | |
| 119 | 2.4/1.8 | 130 | 7 | hsa, ptr, ppa, ggo, mml | br | ion transport (1.5e-09/ 6.5805/ 29/ 663) | voltage-gated potassium channel complex (1.3e-08/7.6e-01/ 11/ 72) | ion channel activity (3.1e-08/ 3.1079/ 19/ 301) | Neuroactive ligand-receptor interaction (2.9e-08/ 2.041/15/206) | 8 (4.8e-02/ 4.817/14/ 496) | |
| 120 | 2.4/1.6 | 125 | 9 | hsa, ptr, ppa, ggo, ppy, mml | br | G-protein coupled receptor protein signaling pathway (5.1e-09/ 4.2107/ 23/ 416) | ion channel complex (1.2e-12/1.8e+00/ 19/ 170) | gated channel activity (1.1e-10/ 2.4601/ 20/ 247) | Neuroactive ligand-receptor interaction (3.8e-10/ 2.094/17/206) | 8 (1.2e-02/ 4.632/15/ 496) | |
| 121 | 2.4/1.6 | 105 | 8 | hsa, ppa, ppy, mml | br | G-protein coupled receptor protein signaling pathway (2.1e-08/ 3.3931/ 20/ 416) | integral to membrane (5.8e-13/3.2e+01/ 70/3638) | G-protein coupled amine receptor activity (9.6e-12/ 0.2438/ 10/ 29) | Neuroactive ligand-receptor interaction (5.1e-12/ 1.665/17/206) | ||
| 122 | 2.4/1.6 | 158 | 6 | hsa | br | oligodendrocyte differentiation (6.6e-04/ 0.2972/ 5/ 27) | intrinsic to membrane (2.9e-06/4.3e+01/ 73/3717) | receptor activity (4.9e-05/10.8772/ 29/ 992) | |||
| 123 | 2.4/1.4 | 124 | 17 | hsa, ptr, ppa, ggo, ppy, mml | br | G-protein coupled receptor protein signaling pathway (1.4e-08/ 4.0472/ 22/ 416) | voltage-gated potassium channel complex (4.3e-11/7.6e-01/ 13/ 72) | voltage-gated cation channel activity (1.2e-11/ 1.1645/ 16/ 118) | Neuroactive ligand-receptor interaction (6.8e-10/ 1.880/16/206) | ||
| 124 | 2.4/1.4 | 112 | 18 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (6.3e-08/ 2.4819/ 17/ 287) | ion channel complex (4.2e-09/1.6e+00/ 15/ 170) | voltage-gated cation channel activity (3.1e-10/ 1.0135/ 14/ 118) | Neuroactive ligand-receptor interaction (1.2e-06/ 1.611/12/206) | 8 (4.3e-02/ 4.150/13/ 496) | |
| 125 | 2.4/1.4 | 326 | 11 | mml | br, cb, ht, kd, lv | deoxyribonucleotide metabolic process (5.9e-03/ 0.5199/ 5/ 23) | mitochondrion (6.5e-04/2.2e+01/ 42/ 931) | deoxynucleoside kinase activity (3.3e-02/ 0.0694/ 2/ 3) | Parkinson's disease (1.6e-02/ 1.539/ 7/ 72) | ||
| 126 | 2.4/1.4 | 196 | 13 | hsa, mml | br, ht, kd, lv, ts | RNA processing (8.9e-03/ 6.4125/ 17/ 413) | intracellular (3.3e-03/1.2e+02/143/8206) | RNA binding (1.0e-02/ 7.2504/ 18/ 478) | |||
| 127 | 2.4/1.2 | 92 | 10 | hsa, ptr, ggo | br | oligodendrocyte differentiation (2.6e-06/ 0.1804/ 6/ 27) | intrinsic to membrane (1.9e-04/2.7e+01/ 47/3717) | signal transducer activity (2.4e-02/ 8.9649/ 19/1344) | |||
| 128 | 2.4/1.2 | 64 | 21 | hsa, ptr, ppa, ggo, ppy, mml | kd, lv | carboxylic acid metabolic process (2.7e-08/ 2.4631/ 17/ 482) | apical part of cell (7.6e-05/8.9e-01/ 8/ 170) | aminopeptidase activity (5.4e-04/ 0.1402/ 4/ 26) | Glycolysis / Gluconeogenesis (4.2e-04/ 0.307/ 5/ 42) | ||
| 129 | 2.4/1.2 | 294 | 15 | hsa, ppa | br, cb, ht, kd, lv, ts | RNA processing (4.1e-08/ 9.2941/ 33/ 413) | nuclear part (5.5e-06/3.2e+01/ 62/1436) | RNA binding (2.6e-03/10.6572/ 25/ 478) | Spliceosome (5.2e-03/ 1.640/ 8/ 85) | ||
| 130 | 2.2/3 | 209 | 3 | ptr, ppa, ggo | ts | M phase (2.1e-04/ 4.0601/ 16/ 313) | flagellum (4.7e-02/3.4e-01/ 3/ 25) | N-acetylmuramoyl-L-alanine amidase activity (2.5e-02/ 0.0537/ 2/ 4) | X (4.8e-02/ 7.187/18/ 481) | ||
| 131 | 2.2/3 | 271 | 4 | hsa, ptr, ppa | ts | sexual reproduction (9.1e-08/ 5.7238/ 25/ 353) | acrosomal vesicle (8.3e-04/6.5e-01/ 6/ 35) | sequence-specific DNA binding (5.7e-06/ 7.8180/ 26/ 460) | X (4.5e-02/ 9.631/22/ 481) | ||
| 132 | 2.2/3 | 158 | 4 | ptr, ppa, mml | ts | sperm motility (7.2e-03/ 0.1128/ 3/ 14) | perinuclear theca (1.2e-03/1.6e-02/ 2/ 2) | microtubule motor activity (3.3e-02/ 0.5026/ 4/ 55) | X (2.1e-05/ 5.606/22/ 481) | ||
| 133 | 2.2/2.8 | 223 | 3 | ptr, mml | ts | sensory perception (2.1e-03/ 5.0171/ 16/ 381) | nucleosome (4.1e-02/3.2e-01/ 3/ 25) | olfactory receptor activity (2.2e-02/ 0.7589/ 5/ 55) | Olfactory transduction (1.6e-03/ 1.001/ 7/ 80) | X (4.1e-05/ 7.942/26/ 481) | |
| 134 | 2.2/2.6 | 353 | 3 | hsa, ptr | lv | small molecule metabolic process (7.2e-18/39.4829/103/1313) | extracellular region (3.3e-09/4.0e+01/ 83/1407) | vitamin binding (3.8e-09/ 3.0700/ 20/ 107) | Complement and coagulation cascades (2.5e-10/ 1.955/17/ 50) | ||
| 135 | 2.2/2.6 | 161 | 5 | ptr, ppa, ggo, mml | ts | sexual reproduction (6.9e-06/ 3.0874/ 16/ 353) | perinuclear theca (1.4e-03/1.7e-02/ 2/ 2) | microtubule motor activity (2.8e-02/ 0.4724/ 4/ 55) | X (4.0e-04/ 5.750/20/ 481) | ||
| 136 | 2.2/2.6 | 440 | 3 | hsa | ht | muscle contraction (1.2e-18/ 5.6223/ 39/ 163) | myofibril (1.7e-26/2.9e+00/ 35/ 86) | structural constituent of muscle (5.9e-11/ 1.0175/ 14/ 29) | Cardiac muscle contraction (9.4e-08/ 2.128/15/ 53) | ||
| 137 | 2.2/2.6 | 377 | 3 | hsa | kd | ion transport (1.7e-09/20.1324/ 55/ 663) | apical part of cell (1.9e-16/5.2e+00/ 34/ 170) | transmembrane transporter activity (9.9e-12/21.0139/ 61/ 712) | Collecting duct acid secretion (5.2e-03/ 0.569/ 5/ 21) | ||
| 138 | 2.2/2.6 | 465 | 3 | ptr, ppa, ggo | ht | generation of precursor metabolites and energy (9.5e-18/ 8.5961/ 46/ 239) | mitochondrion (4.8e-24/3.2e+01/102/ 931) | oxidoreductase activity, acting on NADH or NADPH (3.1e-10/ 2.1199/ 18/ 58) | Parkinson's disease (6.5e-14/ 2.891/24/ 72) | ||
| 139 | 2.2/2.6 | 310 | 3 | hsa, ppa | lv | steroid metabolic process (7.6e-10/ 4.4629/ 25/ 174) | vesicular fraction (2.1e-06/4.3e+00/ 19/ 169) | endopeptidase inhibitor activity (2.4e-06/ 2.5035/ 15/ 103) | Complement and coagulation cascades (2.0e-13/ 1.668/19/ 50) | ||
| 140 | 2.2/2.4 | 336 | 4 | hsa, ptr, mml | lv | small molecule metabolic process (8.9e-19/38.9668/104/1313) | extracellular region (4.3e-10/3.9e+01/ 84/1407) | vitamin binding (4.5e-10/ 3.0309/ 21/ 107) | Complement and coagulation cascades (4.8e-12/ 2.059/19/ 50) | ||
| 141 | 2.2/2.4 | 308 | 3 | ptr, ppa | cb | nucleic acid metabolic process (3.1e-04/60.7687/ 92/2654) | nucleus (4.8e-05/8.6e+01/122/3707) | sequence-specific DNA binding (3.7e-04/10.5501/ 27/ 460) | |||
| 142 | 2.2/2.4 | 317 | 5 | hsa, ptr, ppa | cb | regulation of RNA metabolic process (9.7e-08/31.8962/ 68/1288) | nucleus (3.1e-06/8.8e+01/129/3707) | sequence-specific DNA binding (4.5e-06/11.5588/ 33/ 460) | miR-129/129-5p (3.8e-04/ 8.339/27/ 275) | ||
| 143 | 2.2/2.4 | 265 | 7 | hsa, ptr, ppa, ggo, mml | ts | sexual reproduction (5.1e-22/ 4.2321/ 38/ 353) | flagellum (1.8e-06/3.6e-01/ 7/ 25) | lysozyme activity (2.9e-03/ 0.0921/ 3/ 7) | Oocyte meiosis (9.7e-03/ 0.657/ 5/ 90) | X (4.1e-05/ 9.523/29/ 481) | |
| 144 | 2.2/2.4 | 382 | 3 | hsa | br | ncRNA metabolic process (8.1e-03/ 5.1486/ 15/ 177) | myelin sheath (5.3e-03/3.6e-01/ 4/ 12) | translation initiation factor activity (2.1e-03/ 1.0074/ 7/ 35) | Axon guidance (4.5e-02/ 2.984/ 9/106) | ||
| 145 | 2.2/2.4 | 302 | 4 | mml | kd, lv | carboxylic acid metabolic process (4.6e-04/10.5627/ 27/ 482) | glutamate-cysteine ligase complex (7.7e-03/4.5e-02/ 2/ 2) | pyridoxal phosphate binding (1.1e-02/ 0.9783/ 6/ 43) | |||
| 146 | 2.2/2.4 | 364 | 4 | hsa, mml | lv | steroid metabolic process (6.4e-15/ 5.4546/ 34/ 174) | extracellular region (6.2e-11/4.2e+01/ 90/1407) | endopeptidase inhibitor activity (2.2e-08/ 3.0588/ 19/ 103) | Complement and coagulation cascades (1.1e-11/ 2.177/19/ 50) | ||
| 147 | 2.2/2.4 | 182 | 6 | hsa, ptr, ppa, ggo, mml | ts | sexual reproduction (1.5e-16/ 3.3302/ 29/ 353) | outer dense fiber (3.2e-07/3.7e-02/ 4/ 4) | microtubule motor activity (7.3e-03/ 0.5578/ 5/ 55) | X (6.0e-03/ 6.468/19/ 481) | ||
| 148 | 2.2/2.4 | 411 | 5 | ptr, ppa, ppy | ht | muscle contraction (4.1e-16/ 5.3020/ 35/ 163) | myofibril (1.6e-21/2.7e+00/ 30/ 86) | cytoskeletal protein binding (1.0e-08/13.0762/ 41/ 391) | Hypertrophic cardiomyopathy (HCM) (1.9e-09/ 2.500/18/ 69) | ||
| 149 | 2.2/2.4 | 485 | 3 | hsa, mml | ht | muscle system process (3.4e-22/ 6.5749/ 46/ 177) | contractile fiber (2.2e-30/3.5e+00/ 41/ 94) | structural constituent of muscle (1.9e-14/ 1.0891/ 17/ 29) | Dilated cardiomyopathy (8.4e-13/ 2.966/23/ 72) | ||
| 150 | 2.2/2.4 | 446 | 3 | hsa, mml | kd | ion transport (9.2e-12/23.1946/ 65/ 663) | apical part of cell (7.3e-20/6.0e+00/ 40/ 170) | active transmembrane transporter activity (5.8e-18/ 9.4156/ 49/ 277) | Aldosterone-regulated sodium reabsorption (3.7e-04/ 1.101/ 8/ 33) | ||
| 151 | 2.2/2.4 | 355 | 5 | hsa, ptr, mml | lv | small molecule metabolic process (8.2e-19/41.2893/108/1313) | extracellular region (2.1e-12/4.2e+01/ 93/1407) | vitamin binding (9.9e-10/ 3.1775/ 21/ 107) | Complement and coagulation cascades (1.5e-14/ 2.216/22/ 50) | ||
| 152 | 2.2/2.4 | 320 | 4 | hsa, ptr, ppa | cb | regulation of transcription (1.4e-08/46.6918/ 90/1856) | nucleus (6.6e-08/8.9e+01/136/3707) | transcription cofactor activity (3.0e-05/ 7.4204/ 24/ 289) | Pathways in cancer (3.7e-02/ 5.349/13/270) | miR-129/129-5p (4.9e-05/ 8.227/29/ 275) | |
| 153 | 2.2/2.2 | 332 | 7 | hsa, ptr, ppa, mml | lv | small molecule metabolic process (8.0e-18/38.9668/102/1313) | extracellular region (1.2e-16/3.9e+01/ 98/1407) | vitamin binding (5.0e-11/ 2.9820/ 22/ 107) | Complement and coagulation cascades (2.1e-16/ 2.033/23/ 50) | ||
| 154 | 2.2/2.2 | 297 | 7 | hsa, ptr, ppa, ggo, ppy | cb | regulation of RNA metabolic process (1.3e-05/29.7445/ 59/1288) | nucleus (8.4e-04/8.3e+01/113/3707) | sequence-specific DNA binding (1.9e-04/10.7182/ 28/ 460) | Pathways in cancer (2.7e-02/ 4.505/12/270) | miR-129/129-5p (5.0e-03/ 8.115/24/ 275) | |
| 155 | 2.2/2.2 | 447 | 4 | hsa, ggo | ht | muscle contraction (4.3e-21/ 5.7185/ 42/ 163) | contractile fiber (1.1e-31/3.2e+00/ 41/ 94) | structural constituent of muscle (1.8e-13/ 1.0255/ 16/ 29) | Cardiac muscle contraction (8.7e-12/ 2.128/19/ 53) | ||
| 156 | 2.2/2.2 | 437 | 3 | ppa, ggo | ht | muscle contraction (5.3e-16/ 5.3500/ 35/ 163) | myofibril (2.4e-19/2.9e+00/ 29/ 86) | structural constituent of muscle (8.6e-09/ 0.9698/ 12/ 29) | Oxidative phosphorylation (8.4e-13/ 2.635/22/ 76) | MT (8.2e-06/ 0.359/ 7/ 11) | |
| 157 | 2.2/2.2 | 433 | 7 | ptr, ppa, ggo, ppy, mml | ht | muscle contraction (2.0e-15/ 5.6063/ 35/ 163) | myofibril (1.7e-23/2.8e+00/ 32/ 86) | cytoskeletal protein binding (1.9e-10/13.4335/ 45/ 391) | Parkinson's disease (2.6e-12/ 2.815/22/ 72) | ||
| 158 | 2.2/2.2 | 347 | 3 | ppa, mml | lv | response to wounding (5.3e-12/14.5151/ 50/ 494) | extracellular region (1.2e-11/4.0e+01/ 89/1407) | vitamin binding (1.4e-08/ 2.9624/ 19/ 107) | Complement and coagulation cascades (5.1e-10/ 2.046/17/ 50) | ||
| 159 | 2.2/2.2 | 455 | 3 | hsa, ggo | ht | muscle contraction (3.3e-17/ 5.5583/ 37/ 163) | contractile fiber (1.5e-24/3.3e+00/ 35/ 94) | structural constituent of muscle (5.8e-11/ 1.0149/ 14/ 29) | Parkinson's disease (2.0e-18/ 2.815/28/ 72) | MT (1.0e-05/ 0.381/ 7/ 11) | |
| 160 | 2.2/2.2 | 302 | 7 | hsa, ptr, ppa, ggo | cb | regulation of RNA metabolic process (9.0e-06/30.1242/ 60/1288) | nucleus (9.4e-05/8.5e+01/120/3707) | sequence-specific DNA binding (3.3e-05/10.8863/ 30/ 460) | Long-term potentiation (9.1e-03/ 0.981/ 6/ 53) | miR-129/129-5p (2.8e-03/ 7.778/24/ 275) | |
| 161 | 2.2/2.2 | 400 | 4 | ggo, ppy | kd | sodium ion transport (2.2e-09/ 3.6103/ 22/ 117) | apical plasma membrane (1.5e-13/4.2e+00/ 28/ 135) | active transmembrane transporter activity (2.2e-14/ 8.4285/ 41/ 277) | Systemic lupus erythematosus (1.5e-04/ 1.627/10/ 52) | ||
| 162 | 2.2/2.2 | 409 | 4 | ppy, mml | kd | ion transport (5.1e-10/21.2400/ 58/ 663) | apical part of cell (1.6e-16/5.5e+00/ 35/ 170) | active transmembrane transporter activity (2.9e-15/ 8.7322/ 43/ 277) | Aldosterone-regulated sodium reabsorption (7.5e-04/ 0.886/ 7/ 33) | ||
| 163 | 2.2/2.2 | 439 | 5 | hsa, mml | kd | ion transport (1.5e-16/23.0643/ 74/ 663) | apical part of cell (1.2e-20/6.0e+00/ 41/ 170) | transmembrane transporter activity (3.0e-18/24.3319/ 81/ 712) | Aldosterone-regulated sodium reabsorption (2.8e-04/ 1.058/ 8/ 33) | ||
| 164 | 2.2/2 | 287 | 11 | hsa, ptr, ppa, ggo, ppy, mml | lv | acute inflammatory response (9.4e-20/ 2.0389/ 27/ 78) | extracellular region (1.0e-21/3.4e+01/ 99/1407) | endopeptidase inhibitor activity (1.3e-10/ 2.4941/ 20/ 103) | Complement and coagulation cascades (9.7e-25/ 1.773/28/ 50) | ||
| 165 | 2.2/2 | 324 | 4 | hsa | br | regulation of action potential in neuron (1.5e-03/ 1.2329/ 8/ 51) | myelin sheath (7.2e-06/3.0e-01/ 6/ 12) | signal transducer activity (1.4e-02/32.1754/ 51/1344) | Axon guidance (2.3e-02/ 2.653/ 9/106) | 10 (3.6e-02/12.772/27/ 526) | |
| 166 | 2.2/2 | 287 | 9 | hsa, ptr, ppa, ggo, ppy, mml | cb | nervous system development (1.0e-05/20.3146/ 46/ 927) | nucleus (1.2e-03/7.9e+01/108/3707) | sequence-specific DNA binding (3.5e-05/10.3399/ 29/ 460) | Long-term depression (3.7e-02/ 0.929/ 5/ 54) | miR-129/129-5p (2.4e-02/ 8.002/22/ 275) | |
| 167 | 2.2/2 | 309 | 8 | hsa, ptr, ppa, ggo | cb | regulation of transcription, DNA-dependent (3.0e-05/29.0594/ 57/1253) | nucleus (2.5e-03/8.6e+01/114/3707) | sequence-specific DNA binding (4.4e-05/11.0545/ 30/ 460) | Long-term depression (4.4e-02/ 0.971/ 5/ 54) | miR-129/129-5p (1.7e-03/ 7.965/25/ 275) | |
| 168 | 2.2/1.8 | 470 | 12 | hsa, ptr, ppa, ggo, ppy, mml | ht | muscle contraction (1.6e-17/ 6.1349/ 39/ 163) | myofibril (4.2e-28/3.1e+00/ 37/ 86) | cytoskeletal protein binding (1.4e-13/14.6125/ 53/ 391) | Parkinson's disease (2.4e-12/ 3.135/23/ 72) | ||
| 169 | 2.2/1.8 | 230 | 6 | hsa, ptr, ppa, mml | br | ion transport (5.5e-11/12.0534/ 43/ 663) | ion channel complex (4.7e-11/3.1e+00/ 22/ 170) | gated channel activity (1.6e-10/ 4.5590/ 26/ 247) | Neuroactive ligand-receptor interaction (1.4e-08/ 4.028/21/206) | miR-542/542-3p (4.1e-02/ 2.907/12/ 125) | |
| 170 | 2.2/1.8 | 248 | 5 | hsa | kd, lv | transmembrane transport (4.5e-03/11.6523/ 26/ 587) | intrinsic to membrane (2.5e-03/7.2e+01/ 98/3717) | hexose transmembrane transporter activity (5.4e-03/ 0.2892/ 4/ 15) | Metabolic pathways (8.6e-03/15.109/28/805) | ||
| 171 | 2.2/1.6 | 253 | 9 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (2.1e-10/ 5.7535/ 29/ 287) | ion channel complex (5.3e-12/3.4e+00/ 24/ 170) | gated channel activity (3.5e-11/ 4.9878/ 28/ 247) | Neuroactive ligand-receptor interaction (2.4e-14/ 4.404/29/206) | ||
| 172 | 2.2/1.6 | 235 | 9 | hsa, ppa, ppy, mml | br | synaptic transmission (2.1e-13/ 5.3869/ 32/ 287) | intrinsic to membrane (4.7e-17/7.3e+01/138/3717) | voltage-gated potassium channel activity (4.8e-12/ 1.5469/ 18/ 81) | Neuroactive ligand-receptor interaction (3.2e-12/ 3.920/25/206) | ||
| 173 | 2.2/1.6 | 262 | 6 | hsa | br | oligodendrocyte differentiation (7.5e-04/ 0.5333/ 6/ 27) | membrane (3.1e-08/1.0e+02/149/5148) | receptor activity (2.0e-04/19.4883/ 41/ 992) | Cell adhesion molecules (CAMs) (2.1e-02/ 2.101/ 8/102) | ||
| 174 | 2.2/1.6 | 203 | 8 | ptr, ppa | br | synaptic transmission (1.2e-03/ 4.2305/ 15/ 287) | voltage-gated potassium channel complex (6.2e-06/1.1e+00/ 10/ 72) | potassium channel activity (2.6e-05/ 1.5296/ 11/ 108) | Neuroactive ligand-receptor interaction (6.5e-03/ 2.685/10/206) | ||
| 175 | 2.2/1.6 | 222 | 7 | hsa, ppy, mml | br | synaptic transmission (4.3e-11/ 4.9920/ 28/ 287) | integral to membrane (2.6e-17/6.5e+01/128/3638) | voltage-gated potassium channel activity (1.6e-12/ 1.4359/ 18/ 81) | Neuroactive ligand-receptor interaction (2.0e-13/ 3.759/26/206) | ||
| 176 | 2.2/1.6 | 237 | 9 | hsa, ptr, ppa, ppy, mml | br | synaptic transmission (3.8e-15/ 5.3305/ 34/ 287) | intrinsic to membrane (3.7e-14/7.3e+01/132/3717) | voltage-gated potassium channel activity (2.8e-13/ 1.5099/ 19/ 81) | Neuroactive ligand-receptor interaction (1.7e-10/ 3.920/23/206) | ||
| 177 | 2.2/1.4 | 222 | 18 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (1.3e-13/ 4.9356/ 31/ 287) | voltage-gated potassium channel complex (1.1e-12/1.3e+00/ 17/ 72) | voltage-gated potassium channel activity (9.2e-12/ 1.3692/ 17/ 81) | Neuroactive ligand-receptor interaction (7.0e-10/ 3.813/22/206) | ||
| 178 | 2.2/1.4 | 213 | 8 | hsa, ptr, ggo | br | regulation of action potential in neuron (9.8e-05/ 0.8019/ 8/ 51) | myelin sheath (7.6e-07/2.0e-01/ 6/ 12) | extracellular matrix structural constituent conferring tensile strength (4.5e-02/ 0.0786/ 2/ 5) | 10 (4.7e-02/ 8.410/20/ 526) | ||
| 179 | 2.2/1.4 | 310 | 6 | mml | ht, kd, lv | membrane lipid catabolic process (6.1e-03/ 0.2874/ 4/ 13) | cytoplasmic part (1.4e-02/8.6e+01/110/3895) | Ran guanyl-nucleotide exchange factor activity (3.4e-02/ 0.0707/ 2/ 3) | |||
| 180 | 2.2/1.2 | 468 | 11 | ggo | br, cb, ht, kd, lv, ts | DNA repair (1.3e-03/ 8.1625/ 22/ 238) | plus-end kinesin complex (1.6e-02/7.2e-02/ 2/ 2) | DNA nucleotidylexotransferase activity (2.8e-02/ 0.0709/ 2/ 2) | |||
| 181 | 2.2/1 | 124 | 24 | hsa, ptr, ppa, ggo, ppy, mml | kd, lv | carboxylic acid metabolic process (8.2e-18/ 4.8314/ 35/ 482) | cell fraction (1.4e-05/8.2e+00/ 25/ 825) | catalytic activity (1.4e-08/38.8532/ 72/3901) | Metabolic pathways (9.0e-10/12.591/37/805) | ||
| 182 | 2.2/1 | 420 | 10 | hsa, ppy | br, br, cb, ht, kd, lv | antigen processing and presentation (2.3e-06/ 1.2144/ 11/ 37) | MHC class II protein complex (1.3e-06/2.6e-01/ 6/ 8) | RNA binding (1.4e-03/15.4616/ 33/ 478) | Systemic lupus erythematosus (4.2e-13/ 1.735/19/ 52) | 6 (4.2e-07/23.486/57/ 721) | |
| 183 | 2/2.2 | 466 | 6 | ppy | ht, kd, lv | antigen processing and presentation (6.3e-08/ 1.3562/ 13/ 37) | MHC class II protein complex (2.3e-06/2.9e-01/ 6/ 8) | peptide transporter activity (6.4e-04/ 0.3609/ 5/ 10) | Systemic lupus erythematosus (6.2e-12/ 2.088/19/ 52) | 6 (4.7e-06/25.856/58/ 721) | |
| 184 | 2/2 | 486 | 9 | hsa, ptr, ppa, ggo, ppy, mml | cb | regulation of transcription (6.4e-07/69.1258/115/1856) | nucleus (5.5e-05/1.4e+02/180/3707) | sequence-specific DNA binding transcription factor activity (2.5e-04/27.2357/ 52/ 708) | Glycosphingolipid biosynthesis - lacto and neolacto series (5.2e-03/ 0.575/ 5/ 19) | miR-129/129-5p (1.8e-04/13.537/37/ 275) | |
| 185 | 2/2 | 467 | 4 | hsa | kd, lv | small molecule metabolic process (1.1e-04/48.3859/ 81/1313) | mitochondrion (3.0e-04/3.4e+01/ 59/ 931) | uracil DNA N-glycosylase activity (1.9e-03/ 0.1072/ 3/ 3) | Metabolic pathways (8.3e-04/30.639/52/805) | ||
| 186 | 2/2 | 483 | 5 | hsa | kd, lv | homophilic cell adhesion (4.2e-12/ 4.2585/ 27/ 107) | mitochondrion (1.2e-05/3.7e+01/ 68/ 931) | calcium ion binding (4.5e-04/18.5473/ 39/ 481) | Metabolic pathways (2.3e-05/33.786/61/805) | miR-448 (1.1e-02/13.722/32/ 424) | 5 (2.3e-02/25.197/45/ 660) |
| 187 | 2/1.8 | 458 | 6 | hsa, ptr, ppa, mml | br | synaptic transmission (4.2e-12/ 9.9277/ 41/ 287) | ion channel complex (1.4e-10/6.1e+00/ 29/ 170) | channel activity (2.2e-12/11.6513/ 45/ 322) | Neuroactive ligand-receptor interaction (1.0e-11/ 7.357/33/206) | miR-153 (2.8e-03/21.744/46/ 453) | |
| 188 | 2/1.6 | 430 | 7 | hsa, ptr | br | nervous system development (5.8e-07/30.0619/ 64/ 927) | myelin sheath (3.4e-05/4.1e-01/ 6/ 12) | UDP-galactosyltransferase activity (3.0e-02/ 0.5117/ 4/ 16) | Axon guidance (4.8e-03/ 3.012/11/106) | 10 (7.6e-04/16.898/38/ 526) | |
| 189 | 2/1.6 | 466 | 8 | hsa, ptr, ppa, ppy, mml | br | synaptic transmission (4.8e-17/10.2379/ 49/ 287) | intrinsic to membrane (2.4e-15/1.4e+02/220/3717) | signal transducer activity (1.5e-11/48.1404/102/1344) | Neuroactive ligand-receptor interaction (1.7e-10/ 7.679/32/206) | ||
| 190 | 2/1.6 | 472 | 10 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (3.2e-22/10.4917/ 57/ 287) | plasma membrane (9.6e-22/9.8e+01/191/2624) | gated channel activity (7.7e-18/ 9.1632/ 48/ 247) | Neuroactive ligand-receptor interaction (1.1e-14/ 8.055/39/206) | miR-218 (5.5e-03/28.251/54/ 557) | |
| 191 | 2/1.6 | 460 | 10 | hsa, ptr, ppa, ppy, mml | br | synaptic transmission (3.3e-21/10.2943/ 55/ 287) | plasma membrane (3.0e-20/9.6e+01/185/2624) | gated channel activity (1.4e-17/ 8.9375/ 47/ 247) | Neuroactive ligand-receptor interaction (1.1e-15/ 7.948/40/206) | ||
| 192 | 2/1.6 | 460 | 9 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (1.3e-12/10.0405/ 42/ 287) | plasma membrane (8.1e-14/9.4e+01/166/2624) | gated channel activity (4.5e-15/ 8.8698/ 43/ 247) | Neuroactive ligand-receptor interaction (7.3e-13/ 7.894/36/206) | ||
| 193 | 2/1.6 | 469 | 8 | hsa, ppa, ppy, mml | br | synaptic transmission (4.3e-18/10.4071/ 51/ 287) | intrinsic to membrane (4.0e-17/1.4e+02/227/3717) | gated channel activity (1.2e-11/ 8.9375/ 38/ 247) | Neuroactive ligand-receptor interaction (8.2e-14/ 7.733/37/206) | ||
| 194 | 2/1.4 | 496 | 15 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (2.3e-27/10.9994/ 65/ 287) | plasma membrane (1.9e-27/1.0e+02/213/2624) | gated channel activity (3.0e-18/ 9.5694/ 50/ 247) | Neuroactive ligand-receptor interaction (4.9e-19/ 8.700/46/206) | miR-218 (7.2e-03/30.069/56/ 557) | |
| 195 | 2/1.4 | 409 | 9 | hsa, ptr, ggo | br | nervous system development (1.0e-06/28.5133/ 61/ 927) | myelin sheath (2.4e-05/3.8e-01/ 6/ 12) | ion channel activity (4.3e-03/ 9.1037/ 22/ 301) | Axon guidance (4.5e-02/ 2.984/ 9/106) | 10 (3.1e-02/16.073/32/ 526) | |
| 196 | 2/1.4 | 406 | 10 | hsa, ptr, ggo, ppy | br | nervous system development (3.6e-08/28.6044/ 65/ 927) | intrinsic to membrane (8.1e-08/1.2e+02/172/3717) | potassium channel activity (6.1e-05/ 3.2862/ 15/ 108) | Glycosaminoglycan biosynthesis - keratan sulfate (1.2e-03/ 0.416/ 5/ 14) | 19 (1.3e-03/25.788/50/ 846) | |
| 197 | 2/1.2 | 478 | 20 | hsa, ptr, ppa, ggo, ppy, mml | br | synaptic transmission (1.7e-26/10.7174/ 63/ 287) | neuron projection (1.2e-27/1.2e+01/ 65/ 306) | gated channel activity (2.8e-15/ 9.1632/ 44/ 247) | Neuroactive ligand-receptor interaction (4.3e-16/ 8.539/42/206) |
